|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM310313791 |
| 003 |
DE-627 |
| 005 |
20231225135828.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201907692
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1034.xml
|
| 035 |
|
|
|a (DE-627)NLM310313791
|
| 035 |
|
|
|a (NLM)32449212
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Xudong
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Engineered PD-L1-Expressing Platelets Reverse New-Onset Type 1 Diabetes
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.05.2021
|
| 500 |
|
|
|a Date Revised 03.05.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a The pathogenesis of Type 1 diabetes (T1D) arises from the destruction of insulin-producing β-cells by islet-specific autoreactive T cells. Inhibition of islet-specific autoreactive T cells to rescue β-cells is a promising approach to treat new-onset T1D. The immune checkpoint signal axis programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) can effectively regulate the activity of T cells and prevent autoimmune attack. Here, megakaryocyte progenitor cells are genetically engineered to overexpress PD-L1 to produce immunosuppressive platelets. The PD-L1-overexpressing platelets (designated PD-L1 platelets) accumulate in the inflamed pancreas and may suppress the activity of pancreas autoreactive T cells in newly hyperglycemic non-obese diabetic (NOD) mice, protecting the insulin-producing β-cells from destruction. Moreover, PD-L1 platelet treatment also increases the percentage of the regulatory T cells (Tregs) and maintains immune tolerance in the pancreas. It is demonstrated that the rescue of β-cells by PD-L1 platelets can effectively maintain normoglycemia and reverse diabetes in newly hyperglycemic NOD mice
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a drug delivery
|
| 650 |
|
4 |
|a immune tolerance
|
| 650 |
|
4 |
|a platelets
|
| 650 |
|
4 |
|a programmed death-ligand 1 (PD-L1)
|
| 650 |
|
4 |
|a type 1 diabetes (T1D)
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 700 |
1 |
|
|a Kang, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Jinqiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yan, Junjie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Qian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Hao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Peng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gu, Zhen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 32(2020), 26 vom: 04. Juli, Seite e1907692
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:32
|g year:2020
|g number:26
|g day:04
|g month:07
|g pages:e1907692
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201907692
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 32
|j 2020
|e 26
|b 04
|c 07
|h e1907692
|